Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 1/2021

19.03.2020 | Original Article

Evaluation and Recommendation of the 8th Edition of American Joint Committee on Cancer (AJCC) Staging System for Intrahepatic Cholangiocarcinoma (ICC) in 820 Patients from the Surveillance, Epidemiology, and End Results (SEER) Database

verfasst von: Wu RuiYang, Yang ZhiMing, Feng Jiao, Zhang Liang, Zhang Gang

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

The AJCC made four changes to T category in the 8th AJCC stage for ICC, but this is a topic of debate.

Methods

Data from 820 patients with ICC were extracted from the SEER database. Survival analysis of the 8th AJCC stage was examined.

Results

To verify the four T staging changes by survival analysis: prognosis of patients with tumor size > 5 cm was poorer than that with tumor size ≤ 5 cm (P < 0.05); in N0M0 cohort, there was no significant difference in survival between solitary tumor with vascular invasion and multiple tumors (P = 0.092), tumor perforating the visceral peritoneum with and without involving local extrahepatic structures by direct invasion (P = 0.470), and tumor with and without periductal invasion (PI) (P = 0.220). The prognosis of patients with ≥ 4 positive lymph nodes was relatively poor compared with 1–3 positive lymph nodes (P = 0.037) and similar to patients with stage IV (8th AJCC, P = 0.585).

Conclusion

This study found that there was no significant difference in survival between tumor perforating the visceral peritoneum with and without involving local extrahepatic structures by direct invasion, whereas other T staging changes were effective. The inclusion of the number of positive lymph nodes in the 8th AJCC stage may improve prognostic discrimination in ICC patients.
Literatur
1.
Zurück zum Zitat Khan SA, Toledano MB, Taylor-robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008;10(2):77–82.CrossRef Khan SA, Toledano MB, Taylor-robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008;10(2):77–82.CrossRef
2.
Zurück zum Zitat McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006;15(6):1198–1203.CrossRef McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006;15(6):1198–1203.CrossRef
3.
Zurück zum Zitat Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford) 2015;17(8):669–80.CrossRef Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford) 2015;17(8):669–80.CrossRef
4.
Zurück zum Zitat Meng ZW, Pan W, Hong HJ, Chen JZ, Chen YL. Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems. Medicine (Baltimore) 2017;96(34):e7891.CrossRef Meng ZW, Pan W, Hong HJ, Chen JZ, Chen YL. Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems. Medicine (Baltimore) 2017;96(34):e7891.CrossRef
5.
Zurück zum Zitat Yuan L, Luo X, Lu X, Huang B, Cai Q. Liver resection for intrahepatic cholangiocarcinoma in AJCC-stage IV: an evaluation of the survival benefit and prognostic accuracy of current AJCC staging system on N and M classification. Oncol Rep 2016;36(5):2663–2672.CrossRef Yuan L, Luo X, Lu X, Huang B, Cai Q. Liver resection for intrahepatic cholangiocarcinoma in AJCC-stage IV: an evaluation of the survival benefit and prognostic accuracy of current AJCC staging system on N and M classification. Oncol Rep 2016;36(5):2663–2672.CrossRef
6.
Zurück zum Zitat Amin MB ES, Greene F. AJCC Cancer Staging Manual. 8th ed. New York. Springer International Publishing. 2017.CrossRef Amin MB ES, Greene F. AJCC Cancer Staging Manual. 8th ed. New York. Springer International Publishing. 2017.CrossRef
7.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A III, eds. AJCC cancer staging manual. 7th edn. New York: Springer;2010. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A III, eds. AJCC cancer staging manual. 7th edn. New York: Springer;2010.
8.
Zurück zum Zitat Kang SH, Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB et al. Prognostic comparison of the 7th and 8th editions of the American Joint Commission on Cancer staging system for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2018;25(4):240–248.CrossRef Kang SH, Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB et al. Prognostic comparison of the 7th and 8th editions of the American Joint Commission on Cancer staging system for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2018;25(4):240–248.CrossRef
9.
Zurück zum Zitat Kim Y, Moris DP, Zhang XF, Bagante F, Spolverato G, Schmidt C et al. Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: a surveillance, epidemiology, and end results (SEER) analysis. J Surg Oncol 2017;116(6):643–650.CrossRef Kim Y, Moris DP, Zhang XF, Bagante F, Spolverato G, Schmidt C et al. Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: a surveillance, epidemiology, and end results (SEER) analysis. J Surg Oncol 2017;116(6):643–650.CrossRef
10.
Zurück zum Zitat Spolverato G, Bagante F, Weiss M, Alexandrescu S, Marques HP, Aldrighetti L et al. Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. J Surg Oncol 2017;115(6):696–703.CrossRef Spolverato G, Bagante F, Weiss M, Alexandrescu S, Marques HP, Aldrighetti L et al. Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. J Surg Oncol 2017;115(6):696–703.CrossRef
11.
Zurück zum Zitat Kamarajah SK. Evaluation of the AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): a time to revisit a Dogma? A surveillance, epidemiology, and end results (SEER) analysis. J Gastrointest Cancer 2019;50(3):392–399.CrossRef Kamarajah SK. Evaluation of the AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): a time to revisit a Dogma? A surveillance, epidemiology, and end results (SEER) analysis. J Gastrointest Cancer 2019;50(3):392–399.CrossRef
12.
Zurück zum Zitat Yamamoto Y, Sugiura T, Okamura Y, Ito T, Ashida R, Ohgi K et al. The evaluation of the eighth edition of the AJCC/UICC staging system for intrahepatic cholangiocarcinoma: a proposal of a modified new staging system. J Gastrointest Surg 2019. Yamamoto Y, Sugiura T, Okamura Y, Ito T, Ashida R, Ohgi K et al. The evaluation of the eighth edition of the AJCC/UICC staging system for intrahepatic cholangiocarcinoma: a proposal of a modified new staging system. J Gastrointest Surg 2019.
13.
Zurück zum Zitat Cheng Z, Lei Z, Si A, Yang P, Luo T, Guo G et al. Modifications of the AJCC 8th edition staging system for intrahepatic cholangiocarcinoma and proposal for a new staging system by incorporating serum tumor markers. HPB (Oxford) 2019;S1365-182X(19)30560-X. Cheng Z, Lei Z, Si A, Yang P, Luo T, Guo G et al. Modifications of the AJCC 8th edition staging system for intrahepatic cholangiocarcinoma and proposal for a new staging system by incorporating serum tumor markers. HPB (Oxford) 2019;S1365-182X(19)30560-X.
14.
Zurück zum Zitat Nathan H, Aloia TA, Vauthey JN, Abdalla EK, Zhu AX, Schulick RD et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009;16(1):14–22.CrossRef Nathan H, Aloia TA, Vauthey JN, Abdalla EK, Zhu AX, Schulick RD et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009;16(1):14–22.CrossRef
15.
Zurück zum Zitat Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Izumi N, Kadoya M et al. Proposal of a new staging system for intrahepatic cholangiocarcinoma: analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer 2016;122(1):61–70.CrossRef Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Izumi N, Kadoya M et al. Proposal of a new staging system for intrahepatic cholangiocarcinoma: analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer 2016;122(1):61–70.CrossRef
16.
Zurück zum Zitat Mao K, Liu J, Sun J, Zhang J, Chen J, Pawlik TM et al. Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma. J Gastroenterol Hepatol 2016;31(2):417–26.CrossRef Mao K, Liu J, Sun J, Zhang J, Chen J, Pawlik TM et al. Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma. J Gastroenterol Hepatol 2016;31(2):417–26.CrossRef
17.
Zurück zum Zitat Li X, Lin H, Sun Y, Gong J, Feng H, Tu J. Prognostic significance of the lymph node ratio in surgical patients with distal cholangiocarcinoma. J Surg Res 2019;236:2–11.CrossRef Li X, Lin H, Sun Y, Gong J, Feng H, Tu J. Prognostic significance of the lymph node ratio in surgical patients with distal cholangiocarcinoma. J Surg Res 2019;236:2–11.CrossRef
18.
Zurück zum Zitat Kim SH, Chong JU, Lim JH, Choi GH, Kang CM, Choi JS et al. Optimal assessment of lymph node status in gallbladder cancer. Eur J Surg Oncol 2016;42(2):205–10.CrossRef Kim SH, Chong JU, Lim JH, Choi GH, Kang CM, Choi JS et al. Optimal assessment of lymph node status in gallbladder cancer. Eur J Surg Oncol 2016;42(2):205–10.CrossRef
19.
Zurück zum Zitat Pulitano C, Parks RW. Liver resection for intrahepatic cholangiocellular carcinoma: when is it worthwhile?. World J Surg 2008;32(12):2681–2.CrossRef Pulitano C, Parks RW. Liver resection for intrahepatic cholangiocellular carcinoma: when is it worthwhile?. World J Surg 2008;32(12):2681–2.CrossRef
20.
Zurück zum Zitat Tamandl D, Kaczirek K, Gruenberger B, Koelblinger C, Maresch J, Jakesz R et al. Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma. Br J Surg 2009;96(8):919–25.CrossRef Tamandl D, Kaczirek K, Gruenberger B, Koelblinger C, Maresch J, Jakesz R et al. Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma. Br J Surg 2009;96(8):919–25.CrossRef
21.
Zurück zum Zitat Wakizaka K, Yokoo H, Kamiyama T, Ohira M, Kato K, Fujii Y et al. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers. J Gastroenterol Hepatol 2019;34(6):1074–1080.CrossRef Wakizaka K, Yokoo H, Kamiyama T, Ohira M, Kato K, Fujii Y et al. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers. J Gastroenterol Hepatol 2019;34(6):1074–1080.CrossRef
22.
Zurück zum Zitat Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg 2013;217(4):736–750.CrossRef Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg 2013;217(4):736–750.CrossRef
23.
Zurück zum Zitat Bagante F, Merath K, Squires MH, Weiss M, Alexandrescu S, Marques HP et al. The limitations of standard clinicopathologic features to accurately risk-stratify prognosis after resection of intrahepatic cholangiocarcinoma. J Gastrointest Surg 2018;22(3):477–485.CrossRef Bagante F, Merath K, Squires MH, Weiss M, Alexandrescu S, Marques HP et al. The limitations of standard clinicopathologic features to accurately risk-stratify prognosis after resection of intrahepatic cholangiocarcinoma. J Gastrointest Surg 2018;22(3):477–485.CrossRef
24.
Zurück zum Zitat Uenishi T, Ariizumi S, Aoki T, Ebata T, Ohtsuka M, Tanaka E et al. Proposal of a new staging system for mass-forming intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2014;21(7):499–508.CrossRef Uenishi T, Ariizumi S, Aoki T, Ebata T, Ohtsuka M, Tanaka E et al. Proposal of a new staging system for mass-forming intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2014;21(7):499–508.CrossRef
25.
Zurück zum Zitat Addeo P, Jedidi I, Locicero A, Faitot F, Oncioiu C, Onea A et al. Prognostic impact of tumor multinodularity in intrahepatic cholangiocarcinoma. J Gastrointest Surg 2019;23(9):1801–1809.CrossRef Addeo P, Jedidi I, Locicero A, Faitot F, Oncioiu C, Onea A et al. Prognostic impact of tumor multinodularity in intrahepatic cholangiocarcinoma. J Gastrointest Surg 2019;23(9):1801–1809.CrossRef
26.
Zurück zum Zitat de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011;29(23):3140–5.CrossRef de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011;29(23):3140–5.CrossRef
27.
Zurück zum Zitat Ribero D, Nuzzo G, Amisano M, Tomatis M, Guglielmi A, Giulini SM, et al. Comparison of the prognostic accuracy of the sixth and seventh editions of the TNM classification for intrahepatic cholangiocarcinoma. HPB (Oxford) 2011;13(3):198–205.CrossRef Ribero D, Nuzzo G, Amisano M, Tomatis M, Guglielmi A, Giulini SM, et al. Comparison of the prognostic accuracy of the sixth and seventh editions of the TNM classification for intrahepatic cholangiocarcinoma. HPB (Oxford) 2011;13(3):198–205.CrossRef
28.
Zurück zum Zitat Yamamoto J, Kosuge T, Shimada K, Takayama T, Yamasaki S, Ozaki H et al. [Intrahepatic cholangiocarcinoma: proposal of new macroscopic classification]. Nihon Geka Gakkai Zasshi 1993;94(11):1194–200.PubMed Yamamoto J, Kosuge T, Shimada K, Takayama T, Yamasaki S, Ozaki H et al. [Intrahepatic cholangiocarcinoma: proposal of new macroscopic classification]. Nihon Geka Gakkai Zasshi 1993;94(11):1194–200.PubMed
29.
Zurück zum Zitat Shimada K, Sano T, Sakamoto Y, Esaki M, Kosuge T, Ojima H. Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma. World J Surg 2007;31(10):2016–22.CrossRef Shimada K, Sano T, Sakamoto Y, Esaki M, Kosuge T, Ojima H. Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma. World J Surg 2007;31(10):2016–22.CrossRef
30.
Zurück zum Zitat Meng ZW, Pan W, Hong HJ, Chen JZ, Chen YL. Macroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC/UICC TNM staging system. Oncotarget 2017;8(60):101165–101174.CrossRef Meng ZW, Pan W, Hong HJ, Chen JZ, Chen YL. Macroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC/UICC TNM staging system. Oncotarget 2017;8(60):101165–101174.CrossRef
31.
Zurück zum Zitat Uenishi T, Yamazaki O, Yamamoto T, Hirohashi K, Tanaka H, Tanaka S et al. Serosal invasion in TNM staging of mass-forming intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2005;12(6):479–83.CrossRef Uenishi T, Yamazaki O, Yamamoto T, Hirohashi K, Tanaka H, Tanaka S et al. Serosal invasion in TNM staging of mass-forming intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2005;12(6):479–83.CrossRef
Metadaten
Titel
Evaluation and Recommendation of the 8th Edition of American Joint Committee on Cancer (AJCC) Staging System for Intrahepatic Cholangiocarcinoma (ICC) in 820 Patients from the Surveillance, Epidemiology, and End Results (SEER) Database
verfasst von
Wu RuiYang
Yang ZhiMing
Feng Jiao
Zhang Liang
Zhang Gang
Publikationsdatum
19.03.2020
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 1/2021
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-020-04557-y

Weitere Artikel der Ausgabe 1/2021

Journal of Gastrointestinal Surgery 1/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.